Find out how NAMs are influencing safety assessments and decision-making in the pharmaceutical industry ahead of 2026.

Regulatory planning and development assessment encompass a coordinated suite of methodologies aimed at evaluating the impact, efficiency and equity of planning policies and regulatory interventions.

In 2023, the FDA rejected a small pharmaceutical company's new drug application (NDA) with a Refusal-to-File (RTF) decision. This letter provided information on a range of issues within the submission ...

The National Academies Forum on Drug Discovery, Development, and Translation convened this public workshop to examine the state of the science of drug regulation and consider approaches for enhancing ...

Effective and meaningful public engagement are “foundational principles of Federal regulatory development” and the Biden Administration has sought to remove barriers to public participation in the ...

Let's start with the exciting news about tokenization-related activities. The SFC has issued two important circulars to address the risks and regulatory requirements in this area. The first one ...

There has been a positive change in the Chinese regulators' stance on K-12 non-academic learning services, as evidenced by recent draft regulations. TAL Education Group is expected to report its Q4 FY ...

Following a year of profound geopolitical instability, continued technological disruption, and global economic stress, the Gulf region is strategically using regulatory reform to bolster its presence ...